Orion Oyj (Class B)
Chiusa
102 0.69
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
98.45
Massimo
102
Entrata | 70M 210M |
|---|---|
Vendite | 21M 542M |
P/E Media del settore | 21.357 51.78 |
EPS | 1.19 |
Rendimento da dividendi | 1.8 |
Margine di Profitto | 38.768 |
Dipendenti | 4,215 |
EBITDA | 30M 224M |
Rendimento da dividendi Media del settore | 1.80% 1.96% |
|---|
Capitalizzazione di Mercato | 505M 14B |
|---|---|
Apertura precedente | 101.31 |
Chiusura precedente | 102 |
Orion Oyj (Class B) Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Orion Oyj (Class B) Previsione
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Orion Oyj (Class B)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
